Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ACRS Aclaris Therapeutics, Inc.
$3.12 0.32% +0.01
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ACRS stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 335.9M
Enterprise value 278.0M
Trailing PE -1.8187134502924
Forward PE -3.8749998
PEG Ratio -0.20005847953216
Enterprise to EBITDA -3.755
Enterprise to revenue 35.519
Price to book MRQ 3.6257308
Price to sales TTM 42.91723

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 7.8M
EBITDA 37.7M
Diluted EPS TTM -1.58
Total Cash (MRQ) 90.8M
Current ratio (MRQ) 3.362
Operating Cash Flow (TTM) -47113000

ACRS trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ACRS News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.